BioPharma Solutions

NGS-based detection and discovery solutions for Biopharma, CRO and Drug discovery research fields

Overview

NGS solution specialized for Biopharma/CRO/Drug discovery research fields

Celemics offers an NGS-based development and commercialization service for biopharma companies. With our proprietary technologies, this will enable comprehensive and adequate genomic profiling test, such as stratification of patient cohorts, patient screening for clinical trials, marker discovery, and other researches related to drug development, thereby enhancing the efficiency of NGS solution in diverse parts in biopharma-related sphere.

Image in biopharma-solutions page

Features & Benefits

End-to-End Support from Pilot Trials to Full-Scale Commercialization

Our support for biopharma partners expedites the commercialization process. We help our partners to meet the quality system requirements and country-specific regulations. Our products are tested through our rigorous in-house validation system, and provided to our partners to better ensure the quality of our products and meet their goals and needs.

Quality guaranteed with proof of documentation

As quality control and lot control plays crucial role in successful and accurate clinical research and diagnostics, Celemics keep detailed records of all produced and manufactured products.

 

From kits to bioinformatics, we keep track record of documentation for our lot-control and quality-control processes. 

 

We can provide our customers documentation guaranteeing the expiry date of our products, supporting our customers to conduct best practice in their research and diagnostics journey. 

Composed of commonly tested targets associated with cancer

Celemics’ cancer panels are composed of mutual targets that are commonly known to be associated with cancer. With our exclusive technology for designing probes and panels, you will experience proven performance that detects all kinds of variants, including SNV, CNV, InDel and even for novel variant discovery.

CancerScreen Biomarkers and FDA-Approved Anticancer Agents

CancerScreen
50 Panel
CancerScreen
Core Panel
Biomarkers FDA-approved anticancer agents targeting the corresponding gene
ALK (Fusion) Crizotinib, Ceritinib, Alectinib, Lorlatinib
BRAF Dabrafenib+Trametinib, Vemurafenib+Cobimetinib, Encorafenib+Binimetinib
EGFR Gefitinib, Erlotinib, Afatinib, Osimertinib
ERBB2 Trastuzumab, Pertuzumab, Ado-trastuzumab, Emtansine, Neratinib
KRAS Sotorasib , Cetuximab, Panitumumab
MET Crizotinib
NRAS Cetuximab, Panitumumab
PIK3CA Alpelisib, Copanlisib, Duvelisib
RET (Fusion) Cabozantinib, Vandetanib, LOXO-292, BLU-667
ROS1 (Fusion) Crizotinib, Ceritinib, Entrectinib
FGFR3 Erdafitinib
IDH1/2 Ivosidenib, Enasidenib
NTRK1 (Fusion) Larotrectinib, Entrectinib
PDGFRA Imatinib

Flexible Panel Customization

A flexible customization service where additional genes of interest can be added to the Ready-to-Use panels, or a customized panel is newly designed and manufactured. Prior to designing the panel, our experienced researchers and technicians engage in interactive discussion with customers especially over difficult regions such as GC-rich or homologous regions that other companies often fail to capture.

Ready-to-Use Panels

Specification CancerScreen Core Panel CancerScreen 50 Panel
Gene Count 13 genes 54 genes
Genes APC, BRAF, EGFR, ERBB2, KRAS, MET,
NRAS, PIK3CA, SMAD4, TP53

Fusion : ALK, RET, ROS1

ABL1, AKT1, ALK, APC, ATM, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDK6, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MTOR, MYC, MYCN, NOTCH1, NRAS, NTRK1, PDGFRA, PIK3CA, PTCH1, PTEN, PTPN11, RB1, RET, ROS1, SMAD4, SMO, SRC, STK11, TP53

Fusion : ALK , RET, ROS1, NTRK1

Target size 61 kb + Rearrangement 197 kb + Rearrangement
Mutation type SNV, Indel, CNV, Rearrangement
Sample type FFPE, frozen tissue, cfDNA, RNA
Platform All sequencers from Illumina, ThermoFisher, MGI, and PacBio
Bioinformatics pipeline Primary, Secondary, and Tertiary analysis result

- FASTQ to VCF, VCF to Clinical report

Related Products

Ready-to-use-panel

Comprehensive NGS panel for identifying and characterizing the molecular fingerprint for solid tumors with market-leading sensitivity

Ready-to-use-panel

Clinically validated ctDNA panel with exceptional accuracy, even for ultra-low VAF variant detection

Ready-to-use-panel

Ultimate exonic coverage; industry-leading capture performance and sequencing efficiency accompanied by complete BI solution

Celemics Analysis Service

End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis

Resources

Technical Resources

Flyer_CancerScreen CDx Panel

[Product Overview] Celemics Target Enrichment Panel Overview

[Catalogue] Celemics Products & Service Catalogue_All Products & Service